One of the reasons for the high cost of medical treatment reported by the people is the high price of drugs. Reducing the burden of medical expenses on the public has always been a highly valued issue by the Party and the state. Before the establishment of the National Medical Insurance Bureau, although the prices of drugs had decreased, the situation of inflated prices still existed. In January 2019, the "Notice of the General Office of the State Council on Issuing the Pilot Plan for Centralized Procurement and Use of National Organized Drugs" was issued. Eleven cities (4+7), including Beijing, Tianjin, Shanghai, Chongqing, Shenyang, and Dalian, were selected to select pilot varieties from generic drugs corresponding to generic drugs that have passed quality and efficacy consistency evaluations. The state organized pilot programs for centralized procurement and use of drugs. Centralized procurement, the core is to purchase with quantity, exchange quantity for price, and at the same time, combine bidding and procurement to ensure use; Ensure quality and supply; Policy measures such as ensuring payment collection and reducing transaction costs protect the legitimate rights and interests of enterprises, and are therefore welcomed by enterprises and the market. The pilot work has effectively promoted the return of drug prices to reasonable levels. In September 2019, nine departments including the National Healthcare Security Administration formulated the Implementation Opinions on Expanding the Regional Scope of the State Organized Drug Centralized Purchase and Use Pilot, which clearly defined the promotion of the state organized drug centralized purchase and use pilot centralized purchase in quantity mode nationwide, so that eligible medical institutions throughout the country can provide high-quality and inexpensive pilot drugs, and further reduce the burden of drug use for the masses. Subsequently, the Leading Group of the State Council on Deepening the Reform of the Medical and Health System issued a notice on several policy measures to further deepen the reform of the medical and health system through the use of centralized procurement of drugs, proposing 15 measures to comprehensively deepen the reform of centralized procurement and use of drugs organized by the state, build a national public procurement market for drugs and a multi-party procurement pattern, improve the quality level of drugs, and ensure stable supply of drugs, Promote the linkage of medical care, medical insurance, and medicine, amplify the reform effect, and better promote the solution of the problem of people seeking medical treatment. At the beginning of 2021, the executive meeting of the State Council deployed the normalization and institutionalization of centralized volume procurement of drugs. At the beginning of 2022, the State Council held another executive meeting for special deployment to deepen the reform of centralized volume procurement of drugs and high-value medical consumables. As of May this year, the average price reduction of 333 drugs collected by the national organization has exceeded 50%, and the average price reduction of 8 high-value medical consumables such as heart stents and artificial joints collected has exceeded 80%; Together with local alliance procurement, the cumulative burden reduction is about 500 billion yuan. (Reporter Sun Xiuyan)